HLA-DRB1 and hepatocellular carcinoma: In addition, rs477515-C might facilitate the Th1/Th2 transition via inhibiting the activity of HLA-DRB1 enhancer, reduce the expression of HLA-DRB1, and prompt the immunoselection of HCC-related HBV mutations [7].